Vutrisiran - Latest Advances

Impact of Disease-Modifying Therapies on Imaging Parameters in Cardiac Amyloidosis: A Systematic Review and Meta-Analysis.

Journal: Current problems in cardiology

Published: January 07, 2026

Class-Specific Adverse Events of Patients Treated with Small Interfering RNA Therapeutics: A Disproportionality Analysis of the United States Food and Drug Administration Adverse Event Reporting System Database Based on the MY FAERS Platform.

Journal: Nucleic acid therapeutics

Published: November 22, 2025

Neurological efficacy and safety of RNA therapeutics in hereditary transthyretin amyloidosis: a systematic review and meta-analysis of randomized controlled trials.

Journal: Therapeutic advances in cardiovascular disease

Published: November 12, 2025

Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial.

Journal: Circulation

Published: November 10, 2025

Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.

Journal: Journal of the American College of Cardiology

Published: October 31, 2025

Clinical and radiological stabilization following vutrisiran treatment in transthyretin leptomeningeal amyloidosis: a case report.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Published: October 29, 2025

Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions.

Journal: Frontiers in pharmacology

Published: October 07, 2025

Stabilizers, Silencers, and Disease Stage: Lessons From Recent Trials of ATTR Cardiac Amyloidosis.

Journal: Journal of the American College of Cardiology

Published: October 03, 2025

Vutrisiran improves cardiac structure and function in individuals with transthyretin amyloidosis with cardiomyopathy.

Journal: Nature cardiovascular research

Published: October 02, 2025

REPLY: Vutrisiran in ATTR-CM: Questions on Combination Therapy and Early Biomarker Kinetics.

Journal: Journal of the American College of Cardiology

Published: September 26, 2025

Cost-effectiveness of vutrisiran, tafamidis, and their combination in amyloid transthyretin cardiomyopathy.

Journal: European heart journal. Quality of care & clinical outcomes

Published: September 21, 2025

Acoramidis: A New Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.

Journal: The Annals of pharmacotherapy

Published: September 21, 2025